Bone mineral density and DMPA.
Abstract
The relationship between depot medroxyprogesterone acetate (DMPA) and changes in bone mineral density remains controversial despite a substantial number of studies evaluating this potential association and its clinical relevance. While the majority of prospective studies suggest that DMPA produces a modest decline in bone density, several have failed to confirm this association, and none have documented any clinical consequences. The most recent data indicate that if bone density loss does occur in the presence of DMPA, it is reversible and unlikely to adversely influence clinical events either acutely or at a later time, such as in the postmenopausal period. In a risk:benefit evaluation, it is appropriate to consider any relationship between DMPA and changes in bone mineral density in the context of its established efficacy in pregnancy prevention.
Read the paper
Related studies
- Development of a crushable foam model for human trabecular bone
- Data-driven motion compensation in HR-pQCT.
- Modeling of structure, quality, and function in the orthodontic patient
- Exploring the mechanism of Heidihuang Pill in the treatment of osteoporosis based on network pharmacology, molecular docking, and experimental validation
- Effect of fabric on the accuracy of computed tomography-based finite element analyses of the vertebra
- Use of interventions involving virtual reality tasks during the climacteric: a systematic review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.